ADVERTISEMENT
Lupin, Zydus Lifesciences Among DRChoksey’s Top Picks As Pharma Sector Braces For Q3 — Check Full List
Other notable picks include Alembic Pharma which is expected to benefit from specialty optionality and margin improvement.
07 Jan 2026, 01:21 PM IST 
Save
Lupin remains a key outperformer, backed by strong U.S. complex-generic momentum and upcoming launches,says DRChoksey ahead of Q3 results.
(Photo: Envato)
DRChoksey maintains a constructive stance on companies with strong U.S. portfolios, complex generics, and contract development manufacturign organisation exposure, citing Lupin and Zydus as clear winners on growth visibility and structural margin tailwinds.
